Most autoimmune diabetes occurs in those without a diabetic relative, but few cases are identifiable prospectively. To model general population prediction, 491 consecutive newly diabetic children from all of Sweden were tested for autoantibodies to glutamate decarboxylase (GAD65ab), insulin (IAA), and islet cells (ICA), and for HLA-DQ genotypes by PCR; 415 matched control children were tested in parallel. GAD65ab sensitivity/specificity was 70/96%, versus 84/96% for ICA, 56/97% for IAA, 93/93% (any positive), 39/99.7% (all positive), and 41/99.7% (GAD65ab plus IAA). The latter's 25% predictive value was not improved by requiring concomitant high-risk HLA genotypes. GAD65ab were associated with DQA1 *0501/Bi *0201 (DQ2; P = 0.007) but not DQA1*0301/Bl*0302 (DQ8), and IAA with DQA1*0301/Bl*0302 (DQ8; P = 0.03) but not DQA1*0501/B1*0201 (DQ2). GAD65ab were more prevalent in females than males (79 vs. 63%; P < 0.0001) but did not vary with onset age nor season. Combining the three antibody assays yielded sufficient sensitivity for screening. GADab were relatively sensitive/specific for diabetes, but even with HLA marker combinations yielded predictive values insufficient for early immunointervention in the low-prevalence general population. (J. Clin. Invest. 1995. 95:1505-1511
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fore clinical onset. Through such prediction, we may (a) study early disease pathogenesis in humans, (b) screen large populations to intervene years before clinical onset, and (c) test lowtoxicity immunointervention strategies.
Current studies require 63 cell function below the first percentile to achieve sufficient predictive value for intervention, but prediction earlier in the pathogenesis has many theoretical advantages. More ,6 cells remain, so the secretory load per cell is not excessive (1) lessening /8 cell antigen expression (2) and probably susceptibility to autoimmune killing. Less clonal expansion of autoaggressive cells has occurred, and more noninfiltrated islets remain (3) . Fewer antigens are autoimmune targets (4) so low-toxicity therapies interrupting single antigen responses may be effective.
Most new IDDM occurs in persons without a diabetic relative (5) and peak incidence is at puberty, so studies screening healthy schoolchildren are ideal. However, large studies testing for example 4,000 healthy children, yield only a few prediabetic subjects per year (6, 7) . This is clearly inadequate for testing predictive strategies or immunointervention. Testing relatives of IDDM patients is rewarding because greater disease prevalence allows identification of 20-30 prediabetics in the largest studies (8) . Following them to clinical onset allows study of pathophysiology and marker prevalence during the preclinical phase. However, even dozens of prediabetics is insufficient to study complex combinations of several markers, each positive in only some cases. Also, there is no guarantee that familial and sporadic IDDM have the same marker prevalences.
Given the prolonged course of IDDM, and the fact that 5-10% of the , / cells still remain to be destroyed at clinical onset, children with new-onset IDDM are a reasonable model of prediabetes. In fact, numerous studies of glutamate decarboxylase (GAD) (64 kD) antibodies (9) , competitive insulin autoantibodies (IAA) (10) , and islet cell antibodies (ICA) (11) all suggest that for most patients, autoantibodies at onset correlate to those present much earlier. Therefore, we tested 491 children with new-onset IDDM and 415 healthy control children carefully matched by age, sex, and geography. Subjects were recruited in a population-based manner from all of Sweden. Most came from families without a history of IDDM. This crosssectional population-based study achieved high ascertainment and avoided recruitment bias (6) . We sought to test if prediction is improved by adding 65-kD glutamate decarboxylase autoantibodies (GAD65ab) and HLA genotyping to ICA and IAA already described in these children (6) and to find combinations useful for detecting childhood diabetes.
Methods
Blood samples were obtained from 494 of 515 consecutive newly diagnosed cases (96%) registered from September 1986 through December 1987. Median patient age was 9 yr and the male/female ratio was 1.08. The control group was from two sources. For ethical reasons, control children below age 7 (n = 52, 12% of controls) were included when blood was already being obtained for a non-endocrine and non-infectious medical indication. The remainder of controls (n = 371, 88% of controls) were children aged 7-14 yr selected from the general population as described (6, 12 (ICA) were measured by indirect two-color immunofluorescence using blood group 0 frozen human pancreas as described ( 13 ). One pancreas was used throughout the study. Coded slides were evaluated by two independent observers. Each assay included internal standards. Samples were titrated in doubling dilutions to determine endpoint titer for conversion to Juvenile Diabetes Foundation Units (JDFU) by comparison with an international reference serum as described (6) . Assay standard deviation was 1.0 titration steps, corresponding to a coefficient of variation of 15%. The lower limit of detection was 3 JDFU. The laboratory participates in ICA proficiency workshops. Competitive insulin autoantibodies (IAA) were measured by radiobinding assay using acid-charcoal extraction and cold insulin displacement (A%) as described (14) in a laboratory participating in proficiency workshops. In 414/494 patients, blood was obtained within 10 d of the first insulin injection, which should avoid antibodies to exogenous insulin. IAA were measured in 392/414 of these. The cutoff for positive samples was 0.79%, defined as the 99th percentile among 420 nondiabetic controls.
HLA typing. A total of 425 cases and 367 controls were typed for HLA DQ using polymerase chain reaction combined with sequencespecific oligonucleotide probes (15) and by restriction fragment length polymorphism using DR-and DQ-based probes to confirm haplotypes (16) .
GAD65 antibodies. Details of the immunoprecipitation assay have been described (17 Visible bands at 64 kD were quantified by laser densitometry (2202 Ultroscan, LKB, Sweden). GAD65ab index was calculated from integrated peak areas as described (17) . Intra-assay and inter-assay coefficients of variation were 26 and 29%, respectively. This assay achieved 100% sensitivity and 100% specificity in the first GAD Antibody Workshop (20) .
Statistical analyses. Values are given as mean, range, and standard deviation if normally distributed, otherwise as mean, median, range, and quartile distribution. Differences in antibody levels were tested by the Mann-Whitney U test. Correlations between various antibody levels and between antibody level and age were tested by Spearman rank correlation (rj). Two-tailed probability of P = 0.05 was considered significant. Associations between antibodies and HLA types and between family history and markers were tested using Chi square unless any expected value was < 5, when Fisher's exact test was substituted. Fischer's exact test was used for HLA disease associations, and p values were corrected for the total number of comparisons made (n = 8 for DQa and n = 13 for DQ/6). Positive predictive values (PPV) were calculated as: PPV = (P x a)/{ (Pxa) + [( -P) X (1 -i)] ) where a = sensitivity, /3 = specificity, and P = prevalence. Sensitivity was defined as (cases testing positive/ total cases tested), and specificity as { 1-(controls testing positive/total controls tested) ) . Prevalence (P) was estimated at 0.208% from the formula P = (incidence X mean duration) using the measured incidence of 26/100,000 for 0-15 yr olds in Sweden in 1986-1987 and a mean duration of 8 yr (21). Confidence intervals for all PPV were calculated by applying confidence intervals for proportions to test specificities.
Results
Association of GAD65ab with diabetes. (22) no significant association of GAD65ab prevalence or index with onset age was found in the 0-15 year age range (re, P = 0.82). Prevalence in females (79%) was higher than in males (63%) (P < 0.0001), an effect seen in children of all ages within the study range (Fig. 1 B) . An association between season and IDDM incidence is well known (23) Relationship between the three autoantibody tests. Similar to previous, smaller studies (17, 24, 25) GAD65ab index in the 491 cases was significantly correlated with ICA titer (P < 0.001), but not with IAA A% (P = 0.19). IAA A% and ICA titers also were not correlated (P = 0.48). Too few subjects had autoantibodies to test correlations in the control group.
Importantly, 40/488 (8.2%) patients had GAD65ab without detectable ICA. In patients with negative ICA and weak GAD65ab, the recombinant assay may be more sensitive for GAD65ab than the ICA assay. However, 15 patients with negative ICA had higher GAD65ab levels (index > 0.13), suggesting some GAD epitopes may not be preserved in the ICA assay format. Conversely, 105/488 (21.5%) had ICA without GAD65ab, and 46 of these also were IAA-negative, consistent with ICA assay detection of islet antigen(s) distinct from insulin and GAD (26, 27) .
Combining autoantibody tests to predict IDDM. The relationship between number of positive autoantibody tests (each of ICA, IAA, and GAD65ab) and diabetes is shown in Fig. 2 . Only 33/392 control children were positive for even one test, while 298/386 patients were positive in at least two tests. Sensitivity/specificity of positivity in one, two, or three tests were 93/93%, 75/98.5%, and 39/99.7%, respectively. The latter had predictive value of 24%. ICA, IAA, and GAD65ab analyzed in various combinations to determine disease association are shown in Table I A. Only the "GAD65ab or ICA or IAA" test was over 90% sensitive (potentially useful for screening) while "GAD65ab and IAA" was 99.75% specific. The latter could be useful for low-toxicity intervention, since a specificity of 99.75%, with 90% sensitivity and 0.2% prevalence, achieves 50% predictive value. However, all highly specific combinations were insensitive, so the highest predictive value for any test combination was only 25%. This important "tradeoff " between sensitivity and specificity limited predictive values, especially for higher sensitivity test combinations. It is best shown graphically in Fig. 3, A and B .
Combining HLA and antibody markers to predict IDDM. Combinations of diabetes-associated DQ alleles, ranging from high sensitivity/low specificity to high specificity/low sensitivity (Table I B) , were combined with antibody tests (Table I A) for overall sensitivity, specificity and predictive value. The three most sensitive/specific HLA combinations combined with the four most sensitive/specific antibody combinations are shown in Table I C. Adding these HLA markers to antibody test results increased specificity only at the cost of lowered sensitivity. Predictive values were not improved (Fig. 3, A and B ; open circles). Although not shown in Table I , the 25% PPV of the IAA and GAD65ab combination was also not improved, since the one control subject with both autoantibodies was also DQA1 *0501/DQB1 *0201.
Discussion
The rarity of serum collected from prediabetics in the general population makes evaluation of predictive markers difficult. Since antibodies at onset are generally representative of those in prediabetes (9-11), we analyzed 491 new-onset diabetic cases representing virtually all new childhood diabetes in all of Sweden for 16 mo. To our knowledge this is the largest population-based study of its kind. Most cases occurred in subjects without a family history of diabetes (5).
Sensitive and highly specific tests are critical to prediction in low-prevalence populations. The 492 cases included here allow very accurate measurement of sensitivity. However, specificity is best determined by testing low. prevalence groups where most will never get diabetes (28) such as the 415 control children described above. Test specificity determined from these controls has a much greater impact on predictive value than does sensitivity revealed by cases. The control children were well matched to cases by age, gender, and geography, and were recruited in a nonbiased fashion (6) . This careful design resulted in recruitment of only 415 of a possible 794 control children, leading to wide 95% confidence intervals as shown in Table I . While this is an important theoretical limitation, in reality we tested a large number of controls given the difficulties of blood sampling of healthy children. The current study is cross-sectional, and the predictive values calculated here represent predictive value for detecting newonset diabetes. We assume that autoantibodies present at onset also mark the prediabetic period, so our calculations represent "maximum" prospective predictive value. The true prospective predictive value of these tests must, of course, be confirmed by prospective studies. While we used the estimated population prevalence of diabetes for predictive value calculations, cumulative incidence would be appropriate in studies with prospective follow-up. Since most diabetes under 35 yr of age is autoimmune, it will also be important to validate marker prediction in the 15-35-yr age group.
The classic ICA test (29) using cryosectioned human pancreas is attractive since antibodies to multiple,6 cell components are detected simultaneously. However, antibody tests using distinct recombinant antigens are independent of each other as determined by correlation. This independence is likely the rea- Number of ab tests positive 
